<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30061257</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>08</Month>            <Day>08</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1791-7530</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>38</Volume>                    <Issue>8</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                    </PubDate>                </JournalIssue>                <Title>Anticancer research</Title>                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.</ArticleTitle>            <Pagination>                <MedlinePgn>4839-4845</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.12795</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The combination of platinum with 5-fluorouracil has scarcely been studied in metastatic breast cancer. As this combination does not lead to significant hepatic metabolism, in some clinical situations it may prove useful, especially in cases with liver dysfunction and an urgent clinical need for rapid tumor shrinkage. A retrospective study was conducted to evaluate the efficacy and safety of the combination of cisplatin and 5-fluorouracil in patients with metastatic breast cancer with significant alterations of biochemistry.</AbstractText>                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A total of 109 patients with metastatic breast cancer and liver dysfunction were treated; time-to-progression, overall survival and trends in liver function were evaluated.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The median time-to-progression was 3.4 months, and median overall survival was 7.8 months. About 50% of patients obtained a complete, partial or stable biochemical response and 24 patients were subsequently able to receive additional therapies.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results show that this therapeutic doublet represents a clinically effective, safe and well-tolerated treatment option for patients with metastatic breast cancer and liver dysfunction.</AbstractText>                <CopyrightInformation>CopyrightÂ© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rossi</LastName>                    <ForeName>Lorenzo</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy lorenzo.rossi@uslcentro.toscana.it.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Oncology of Southern Switzerland (IOSI), Bellinzona, Switzerland.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Breast Unit of Southern Switzerland (CSSI), Lugano, Switzerland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Biagioni</LastName>                    <ForeName>Chiara</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McCartney</LastName>                    <ForeName>Amelia</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Moretti</LastName>                    <ForeName>Erica</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pestrin</LastName>                    <ForeName>Marta</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sanna</LastName>                    <ForeName>Giuseppina</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Risi</LastName>                    <ForeName>Emanuela</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Malorni</LastName>                    <ForeName>Luca</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>DI Leo</LastName>                    <ForeName>Angelo</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Biganzoli</LastName>                    <ForeName>Laura</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D064888">Observational Study</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Greece</Country>            <MedlineTA>Anticancer Res</MedlineTA>            <NlmUniqueID>8102988</NlmUniqueID>            <ISSNLinking>0250-7005</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>Q20Q21Q62J</RegistryNumber>                <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>U3P01618RT</RegistryNumber>                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">5-fluorouracil</Keyword>            <Keyword MajorTopicYN="N">Metastatic breast cancer</Keyword>            <Keyword MajorTopicYN="N">cisplatin</Keyword>            <Keyword MajorTopicYN="N">liver metastases</Keyword>            <Keyword MajorTopicYN="N">salvage chemotherapy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30061257</ArticleId>            <ArticleId IdType="pii">38/8/4839</ArticleId>            <ArticleId IdType="doi">10.21873/anticanres.12795</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>